Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DUBLIN, Ohio, Nov. 11, 2020 /PRNewswire/ -- Cardinal Health (NYSE: CAH) has reached an agreement with the Centers for Disease Control and Prevention (CDC) to act as a network administrator in Phase 2 of the Federal Pharmacy Partnership Strategy for COVID-19, which will enable retail...

Cardinal Health Partners with CDC to Support Vaccine Access for Pharmacies

After years of underperformance vs. the U.S. stock market, Cardinal may be on the takeoff runway. Two positive catalysts have appeared in early November.

The Bottom Fishing Club: Cardinal Health

Align Technology

CAH vs. ALGN: Which Stock Is the Better Value Option?

CAH vs. ALGN: Which Stock Should Value Investors Buy Now?

Is (CAH) Outperforming Other Medical Stocks This Year?

Has Cardinal Health (CAH) Outpaced Other Medical Stocks This Year?

Cardinal Health, Inc. (CAH) CEO Mike Kaufmann on Q3 2020 Results - Earnings Call Transcript

Shares of Cardinal Health Inc. rallied 5.0% in premarket trading Thursday, after the health care services company reported a fiscal first-quarter adjusted profit and revenue that rose above expectations, and raised its full-year earnings outlook. The company reported a net loss that narrowed to $253 million, or 86 cents a share, from a loss of $4.92 billion, or $16.65 a share, as the company recorded a $1.02 billion charge in connection with opioid lawsuits this year, after a $5.63 billion charge last year.

Cardinal Health records $1 billion opioid-related charge, but stock surges as adjusted profit beats forecasts

DUBLIN, Ohio, Nov. 5, 2020 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported first quarter fiscal year 2021 revenues of $39.1 billion, an increase of 5% from the first quarter of last year. First quarter GAAP operating loss was $624 million due to a $1.0 billion pre-tax accrual...

Cardinal Health Reports First Quarter Fiscal 2021 Results

AbbVie

Aflac

Amcor Plc

Franklin Resources

Chevron

Federal Realty Investment Trust

Johnson & Johnson

Realty Income Corp

People's United Financial

Raytheon Technologies

AT&T

Walgreens

Exxon Mobil

"S&P 500® Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years."---us.spindices.com. The 65 Aristocrats of November 2020 represent ten of eleven Morningstar Sectors (no Technology). Broker targeted-top-ten net-gainers ranged 19.36%-45.91% topped by XOM & CVX 11/3/20.

65 November Dividend Aristocrats

Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Cardinal Health (CAH) Ahead of Earnings?

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

AmerisourceBergen

Becton, Dickinson and Co.

Cooper Companies

Henry Schein

Labcorp Holdings Inc

McKesson

Patterson Companies

West Pharmaceutical Services

DENTSPLY SIRONA

3 Dental Supplies Stocks Set to Shine on the Industry's Upturn

In this article we are going to use hedge fund sentiment as a tool and determine whether Cardinal Health, Inc. (NYSE:CAH) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds' picks don't beat the market 100% of the time, but their consensus picks have historically done very well and have outperformed the market after adjusting for risk.

Were Hedge Funds Right About Piling Into Cardinal Health, Inc. (CAH)?

Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cardinal (CAH) Moves to Buy: Rationale Behind the Upgrade

American Water Works

Newmont Mining

Pool

Although it is rare to see firms raising dividends this year, Newmont Corporation (NEM), Pool Corporation (POOL), Cardinal Health (CAH) and American Water Works (AWK) have come up as exceptions.

4 Dividend Hikers to Bet On Amid Prolonged Uncertainty

AEGON

Flowserve

Top Ranked Income Stocks to Buy for October 16th

Accuray

DaVita

These three MedTech stocks are expected to grow post their Q3 earnings release.

3 Best MedTech Value Stocks to Buy Ahead of Q3 Earnings

Colgate-Palmolive

Kimberly-Clark

McDonald's

Investor sentiment has shifted to a protective stance under the context of ever-rising tensions between the U.S. and China. In this environment, investors should consider stocks to buy now from a list of stable dividend aristocrats.

8 Dividend Aristocrat Stocks to Buy Now

"S&P 500 Dividend Aristocrats measure performance of S&P 500 companies that have increased dividends every year for 25 consecutive years." - us.spindices.com.

65 Dividend Aristocrats Optimal October Outcomes

CVS Health

Diageo

General Dynamics

Orrstown Financial

Vanguard High Dividend Yield ETF

Essential Utilities

In total, my dividend stock purchases of VYM totaled $1,140.63, acquiring 14 total shares.

Dividend Stock Purchase: Lanny's September 2020 Summary

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.

Here's Why You Should Retain Cardinal Health Stock for Now

Cisco Systems

JPMorgan Chase & Co

W. P. Carey

With the S&P 500 averaging a dividend yield of 1.8%, the hunt for yield can be a difficult one. Valuation is also an issue as the average price-earnings ratio for the market index approaches 29.

News for Cardinal Health Stock (CAH)